As of June 11, 2019, Merck’s KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (CPS ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression. Returning guest Dr. Danny Rischin, Director of the Department of Medical Oncology, Peter MacCallum Cancer Centre (Melbourne, Australia) discusses the final analysis of the Phase 3 KEYNOTE-048, KEYTRUDA study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Professor Danny Rischin is the Director of the Division of Cancer Medicine and Head of the Department of Medical Oncology at Peter MacCallum Cancer Center. He is also a consultant Medical Oncologist at the Mercy Hospital for Women. He holds an academic appointment as Professor of Medicine at The University of Melbourne and in 2011 was appointed an Associate Editor of the Journal of Clinical Oncology. Professor Rischin graduated from Monash University and completed his internal medicine and medical oncology training in Melbourne and Toronto. He was Chair of the ANZGOG RAC from 2002 till 2011 and has been an executive member of ANZGOG since its inception.